Key result
APPL1-C/APPL2-A minor-allele combination linked to ~150% higher NAFLD risk versus reference alleles.
Why the study?
The role of genetic variation in APPL1 and APPL2 loci in the occurrence and severity of non-alcoholic fatty liver disease (NAFLD) was not well established.
Does genetic variation in APPL1/APPL2 loci increase the risk of NAFLD in Caucasian subjects?
Case-Control (n=454)
Does genetic variation in APPL1/APPL2 loci increase the risk of NAFLD in Caucasian subjects?
The APPL1-C/APPL2-A allele combination is associated with an increased risk of NAFLD, higher ALT levels, and more severe hepatic steatosis, suggesting a genetic predisposition linked to impaired adiponectin signaling.
Answers are grounded in this paper and cite their sources.
APPL1/APPL2 variants were associated with NAFLD; leaves open causal role pending larger validation studies.
The importance of genetics and epigenetic changes in the pathogenesis of non alcoholic fatty liver disease (NAFLD) has been increasingly recognized. Adiponectin has a central role in regulating glucose and lipid metabolism and controlling inflammation in insulin-sensitive tissues and low adiponectin levels have been linked to NAFLD. APPL1 and APPL2 are adaptor proteins that interact with the intracellular region of adiponectin receptors and mediate adiponectin signaling and its effects on metabolism. The aim of our study was the evaluation of a potential association between variants at APPL1 and APPL2 loci and NAFLD occurrence. The impact on liver damage and hepatic steatosis severity has been also evaluated. To this aim allele frequency and genotype distribution of APPL1- rs3806622 and -rs4640525 and APPL2-rs 11112412 variants were evaluated in 223 subjects with clinical diagnosis of NAFLD and compared with 231 healthy subjects. The impact of APPL1 and APPL2 SNPs on liver damage and hepatic steatosis severity has been also evaluated. The minor-allele combination APPL1-C/APPL2-A was associated with an increased risk of NAFLD (OR = 2.50 95% CI 1.45-4.32; p<0.001) even after adjustment for age, sex, body mass index, insulin resistance (HOMA-IR), triglycerides and adiponectin levels. This allele combination carrier had higher plasma alanine aminotransferase levels (Diff = 15.08 [7.60-22.57] p = 0.001) and an increased frequency of severe steatosis compared to the reference allele combination (OR = 3.88; 95% CI 1.582-9.531; p<0.001). In conclusion, C-APPL1/A-APPL2 allele combination is associated with NAFLD occurrence, with a more severe hepatic steatosis grade and with a reduced adiponectin cytoprotective effect on liver.
No takes yet. Share an insight, caveat, or question.
Barbieri et al. (2013) conducted a case-control in Non-Alcoholic Fatty Liver Disease (n=454). APPL1-C/APPL2-A allele combination vs. APPL1-G/APPL2-G reference allele combination was evaluated on Occurrence of NAFLD (OR 2.50, 95% CI 1.45-4.32, p=<0.001). The minor-allele combination APPL1-C/APPL2-A was associated with a increased risk of NAFLD compared to the reference allele combination.
Synapse has enriched 10 related papers. Consider them for comparative context: